Delivery of Adjuvant Sequential Dose-Dense FEC–Doc to Patients With Breast Cancer Is Feasible, but Dose Reductions and Toxicity Are Dependent on Treatment Sequence

Breast Cancer Research and Treatment - Netherlands
doi 10.1007/s10549-008-9970-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Subclinical Cardiotoxicity Following Adjuvant Dose-Escalated FEC, High-Dose Chemotherapy, or CMF in Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
2000English

Maintaining Dose Intensity of Adjuvant Chemotherapy in Older Patients With Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2018English

Randomised Trial: Survival Benefit and Safety of Adjuvant Dose-Dense Chemotherapy for Node-Positive Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
2006English

F01*Dose-Dense Adjuvant Chemotherapy, Treatment-Induced Amenorrhea and Overall Survival in Premenopausal Breast Cancer Patients: A Pooled Analysis of the MIG1 and GIM2 Phase 3 Studies

Annals of Oncology
MedicineOncologyHematology
2016English

Pulmonary Toxicity of High-Dose Chemotherapy for Breast Cancer: A Non-Invasive Approach to Diagnosis and Treatment

Bone Marrow Transplantation
TransplantationHematology
1997English

Breast Size Impact on Adjuvant Radiotherapy Adverse Effects and Dose Parameters in Treatment Planning

Radiology and Oncology
Nuclear MedicineRadiologyImagingOncology
2018English

Impact of Patient and Treatment Characteristics on Heart and Lung Dose in Adjuvant Radiotherapy for Left-Sided Breast Cancer

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2019English

High Dose, Dose-Intensive Chemotherapy With Doxorubicin and Cyclophosphamide for the Treatment of Advanced Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
1993English

Neratinib in Adjuvant Treatment of Patients With HER2-positive Breast Cancer — Less Is More?

Oncology in Clinical Practice
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy